PureTech Health (PRTC) AI Stock Analysis

• Market Cap: £307.44M
• Dividend Yield: N/A
• Average Volume (3M): 778.48K
• Price to Earnings (P/E): 7.8
• Beta (1Y): 1.81
• Revenue Growth: 38.80%
• EPS Growth: N/A
• Country: UK
• Employees: 80
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): 0.30
• Shares Outstanding: 240,189,450
• 10 Day Avg. Volume: 276,813
• 30 Day Avg. Volume: 778,478
• PEG Ratio: 0.08
• Price to Book (P/B): 1.09
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £455.00
• Price Target Upside: 247.86% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

PureTech Health's overall stock score reflects a company with strong strategic achievements and financial stability, but facing challenges in profitability, cash flow sustainability, and market valuation. Key strengths include successful clinical trials and a robust cash position, while high trial costs and volatile income pose risks.

PureTech Health Business Overview & Revenue Model

Company Description

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

PureTech Health generates revenue through a multi-faceted business model that includes the development and commercialization of its proprietary drug candidates, strategic partnerships, and equity stakes in its Founded Entities. The company derives income from milestone payments and royalties from its partnered programs, as well as potential product sales once its therapeutics are commercialized. Additionally, PureTech benefits financially from its equity interests in Founded Entities, which are companies that it has helped to establish and advance through early development stages. These entities can provide returns through potential exits, such as public offerings or acquisitions.

PureTech Health Financial Statement Overview

Summary

PureTech Health displays mixed financial performance with strong liquidity but challenges in profitability and cash flow. Positive cash reserves and low leverage provide stability, though inconsistent revenue and high operational losses highlight significant risks.

Income Statement

PureTech Health's income statement shows a volatile revenue base with a significant increase from 2023 to 2024. The gross profit margin is positive, but the company is operating at a loss with negative EBIT and EBITDA margins. Although the net profit margin turned positive in 2024, the overall profitability remains a concern due to inconsistent revenue and high operational losses.

Balance Sheet

The balance sheet reflects a strong liquidity position with substantial cash reserves, resulting in a negative net debt. While the debt-to-equity ratio is low, indicating prudent leverage, the equity ratio has decreased, suggesting a decline in asset efficiency. The company's return on equity is volatile, driven by fluctuating net income, indicating instability in shareholder returns.

Cash Flow

Cash flow analysis shows challenges with consistent negative free cash flow, though there was a significant increase in free cash flow from 2023 to 2024. The operating cash flow remains negative, indicating operational cash burn. The company’s cash flow management is buoyed by financing and investing activities, but sustainable operational improvements are needed.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
468.00K	4.32M	750.00K	2.09M	9.98M	8.34M
	Gross Profit
-81.55M	4.32M	-92.91M	-150.34M	-100.49M	8.34M
	EBIT
-136.43M	-136.09M	-146.20M	-197.81M	-150.28M	-119.53M
	EBITDA
-133.15M	37.38M	-17.68M	-79.94M	-46.95M	-144.76M
	Net Income Common Stockholders
-82.47M	53.51M	-65.70M	-37.06M	-62.71M	4.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
280.57M	367.31M	327.14M	350.10M	465.71M	403.88M
	Total Assets
298.75M	602.63M	693.97M	702.65M	946.01M	989.99M
	Total Debt
6.95M	22.36M	25.34M	46.87M	52.02M	76.62M
	Net Debt
-55.11M	-258.28M	-165.74M	-102.99M	-413.68M	-327.26M
	Total Liabilities
206.34M	194.70M	235.74M	155.06M	361.86M	336.45M
	Stockholders Equity
177.67M	414.71M	464.07M	542.22M	593.51M	669.75M
Cash Flow		Free Cash Flow
-120.80M	-134.38M	-106.16M	-180.97M	-163.94M	-137.25M
	Operating Cash Flow
-120.80M	-134.37M	-105.92M	-178.79M	-158.27M	-131.83M
	Investing Cash Flow
131.62M	240.89M	68.99M	-107.22M	197.38M	364.48M
	Financing Cash Flow
-52.86M	-16.96M	78.14M	-29.83M	22.73M	38.87M

PureTech Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 130.80
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRTC, the sentiment is Positive. The current price of 130.8 is above the 20-day moving average (MA) of 126.28, above the 50-day MA of 128.62, and below the 200-day MA of 148.02, indicating a neutral trend. The MACD of -0.37 indicates Negative momentum. The RSI at 54.12 is Neutral, neither overbought nor oversold. The STOCH value of 63.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:PRTC.

PureTech Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVXP	78 Outperform	£146.30M	18.63	69.08%	5.61%	0.49%	-9.52%
PRTC	58 Neutral	£307.44M	7.82	11.74%	―	38.80%	―
ONT	58 Neutral	£1.24B	―	-23.77%	―	7.97%	12.94%
Sector *	52 Neutral	$5.04B	3.15	-44.58%	2.85%	16.08%	-0.27%
SCLP	46 Neutral	£94.35M	―	167.16%	―	-100.00%	-23.91%

PureTech Health Corporate Events

PureTech Health Unveils Research on Idiopathic Pulmonary Fibrosis Challenges

PureTech Health has published new research in collaboration with experts and the Pulmonary Fibrosis Foundation, revealing critical gaps in the diagnosis, treatment, and quality of life for individuals with idiopathic pulmonary fibrosis (IPF). The study highlights the need for enhanced education, patient-focused treatment plans, and more effective therapies, emphasizing the importance of integrating patient perspectives into care strategies to improve outcomes and quality of life for those affected by IPF.

Spark’s Take on GB:PRTC Stock

According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.

PureTech Health’s overall score reflects a blend of mixed financial performance, technical analysis indicating potential downward pressure, and a strong valuation suggesting undervaluation. Earnings call insights reinforce strategic achievements and financial strength but point to ongoing market valuation challenges and high trial costs. The lack of dividend yield and need for external funding for future trials are also significant considerations.

To see Spark’s full report on GB:PRTC stock, click here.

PureTech Health to Present Promising IPF Trial Results at ATS Conference

PureTech Health announced that it will present results from its Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100) at the American Thoracic Society International Conference. The trial demonstrated significant efficacy in stabilizing lung function decline in idiopathic pulmonary fibrosis (IPF) patients over 26 weeks, suggesting deupirfenidone could become a new standard of care. The company plans to meet with the FDA to discuss a potential Phase 3 trial by the end of 2025, aiming to provide a transformative treatment option for IPF patients.

PureTech Health Reports Major Milestones and Strong Financial Position in 2024

PureTech Health announced significant achievements in 2024, including FDA approval for Cobenfy™, positive Phase 2b results for deupirfenidone in IPF, and promising data for LYT-200 in cancer treatment. The company’s financial strength is underscored by a robust cash position, supporting operations through 2027. PureTech’s strategic focus is on advancing its pipeline, securing external funding for Phase 3 trials, and maintaining capital efficiency to drive long-term growth and shareholder value.

Citigroup Adjusts Voting Rights in PureTech Health

PureTech Health PLC has announced a change in its major holdings, as Citigroup Inc. has acquired or disposed of voting rights, resulting in a total of 5.017608% of voting rights held. This adjustment in voting rights reflects Citigroup’s strategic positioning and may influence PureTech’s shareholder dynamics and decision-making processes.

PureTech Health Enhances Market Strategy with New Corporate Broker Appointment

PureTech Health has appointed Peel Hunt as its Joint UK Corporate Broker alongside UBS, a strategic move expected to enhance its market presence and investor relations. This appointment reflects PureTech’s ongoing efforts to strengthen its corporate operations and could potentially impact its positioning within the biotherapeutics industry.

PureTech Health in Talks for Potential Acquisition by Nordic Capital

PureTech Health has confirmed discussions with Nordic Capital regarding a potential cash offer to acquire the entire share capital of the company. While no firm offer has been made, the announcement has implications for PureTech’s market positioning and could affect stakeholders depending on the outcome of these discussions.

Seaport Therapeutics Strengthens Leadership with New Audit Committee Chair

Seaport Therapeutics, a clinical-stage biopharmaceutical company and a Founded Entity of PureTech Health, has appointed Robert J. Hombach as the Chair of its Audit Committee. Hombach brings over 30 years of financial and operational expertise in the biotech sector, having held significant roles at companies like Baxter and Baxalta. His appointment is expected to bolster Seaport’s financial oversight as it progresses its pipeline of neuropsychiatric medicines. This strategic move highlights Seaport’s commitment to advancing its innovative Glyph technology platform, which aims to deliver transformative treatments for neuropsychiatric conditions.

PureTech Health Updates on Share Capital and Voting Rights

PureTech Health announced its total voting rights and share capital as of February 28, 2025, with 257,927,489 issued shares and 240,189,449 voting rights. This disclosure is crucial for shareholders to determine their reporting obligations under the FCA’s rules, impacting stakeholder transparency and engagement.

PureTech Health Announces Vesting of RSUs for Key Executives

PureTech Health announced that restricted share units (RSUs) granted to certain directors and managerial staff in 2022 have vested as of February 2025, following the fulfillment of performance conditions. This vesting resulted in the issuance of ordinary shares to key executives, reflecting the company’s commitment to rewarding leadership and aligning managerial interests with shareholder value, potentially enhancing its market position and stakeholder confidence.

PureTech Health to Participate in Global Healthcare Conference

PureTech Health announced its participation in the upcoming Leerink Partners Global Healthcare Conference, where key executives will engage in a fireside chat. This event underscores PureTech’s active role in the healthcare industry, potentially enhancing its visibility and influence among stakeholders and investors.